Other
Poor Graft Function
0
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Poor Graft Function is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Not yet recruiting2 · 50%
Terminated1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05669079·100 enrolled
Decitabine for Poor Graft Function Post Allo-HSCT
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)